Get started
ArcticZymes Technologies ASAArcticZymes Technologies ASAArcticZymes Technologies ASA

ArcticZymes Technologies ASA

No trades
See on Supercharts
OverviewFinancialsNewsDocumentsIdeasDiscussionsTechnicalsForecastSeasonals

AZT trade ideas

ArcticZymes $AZT Q1 2021 stunning Q1 presentation, up 22% !!!AZTY reported sales of NOK 40.4 million (18.5) and an EBITDA of NOK 25.8 million (9.0) for the first quarter of 2021. Highlights from Q1 2021 · ArcticZymes Technologies (AZT) had Q1 sales of NOK 40.4 million growing by 119% (Q1 2020: NOK 18.5 million) · Coronavirus-related sales are estimated at NOK 16.5 million in Q1 2021 (NOK 3.8 million in Q1 2020) · Gross profit improved to NOK 39.9 million with 99% margin (Q1 2020: NOK 18.5 Million) · AZT delivered a positive EBITDA of NOK 25.8 million (Q1 2020: NOK 9.0 million) · Cash-flow for Q1 was positive NOK 23.2 million (Q1 2020: NOK 4.4 million) giving a cash balance of NOK 163.3 million (Q1 2020: NOK 35.7 million) · Successfully upscaled the SAN HQ production process CEO Jethro Holter comments: "We are delighted with the performance of our first quarter as a pure enzymes company. The ArcticZymes team has delivered the best ever quarterly performance achieving sales revenues of 40 million NOK and an EBITDA of 26 million NOK. All market segments have experienced quarterly growth including re-establishment of molecular research sales to pre-pandemic levels. Furthermore, the SAN HQ enzyme production process was successfully upscaled 100 -fold. The innovation pipeline and the infrastructure expansion project of R&D and operations are progressing. Such activities are key to leveraging the greater potential ArcticZymes Technologies can accomplish through organic growth."
OSL:AZT
by savepiginvest
ArcticZymes $AZT Q3 2020 reportHighlights for Q3 2020 • Annual group sales exceed 100 MNOK for the first time • Gross profit for the Group improved 65% to NOK 26.0 million (Q3 2019: NOK 15.7 million) • ArcticZymes had Q3 sales of NOK 19.5 million growing by 63% (Q3 2019: NOK 12.0 million) • Biotec BetaGlucans had Q3 sales of NOK 11.2 million growing by 7% (Q3 2019: NOK 10.5 million) • Upsides relating to COVID-19 pandemic is estimated at NOK 4 million for ArcticZymes and NOK 1.25 million for consumer health • The Group delivered positive EBITDA with NOK 10.1 million (Q3 2019: NOK 0.8 million) • Cash-flow for Q3 was positive NOK 13.6 million (Q3 2019: NOK 0.7 million) giving a cash balance of NOK 69.7 million (Q3 2019: NOK 22.1 million)
OSL:AZT
by savepiginvest
1
ArcticZymes turnaround & firing on all cylindersThe Turnaround of ArcticZymes is now definitive. For the second quarter we see impressive growth and the company is firing on all cylinders. Opex (cost) going down while earnings as well as profits surge. ArcticZymes Q2 report Sales of NOK 44.3 million (16.9) +262% EBITDA of NOK 27.2 million (-0.5) Cash-flow for the Q2 was NOK 20.4 million (-6.8) Cash at hand NOK 56,1 million Gross margin 90% CEO Jethro Holter says in the earnings call: "The main growth driver has been sales of the Salt Active Nuclease (SAN) products to the therapeutics segment. The SAN products continue to attract new customers who are developing gene therapies and vaccines. Furthermore, our well-established customers are regularly submitting substantially larger orders as they advance their development programs." Full report pdf here: newsweb.oslobors.no text: newsweb.oslobors.no
OSL:AZTLong
by kulturdesken
2
ArcticZymes is the Covid-19 stock that is valued at 197 mUSDArcticZymes has entered into an agreement with ReiThera to supply its SAN product for ReiThera’s COVID-19 vaccine candidate Tromsø, 02 July, 2020: ArcticZymes AS (OSE:AZT), a subsidiary of ArcticZymes Technologies ASA, announces that it has entered into a supply agreement with vaccine specialist ReiThera Srl (Rome, Italy) for the supply of Salt Active Nuclease (SAN-HQ) to be used in the development and manufacturing of ReiThera’s novel vaccine candidate against COVID-19. The vaccine candidate, which is based on ReiThera’s viral vector technology, is scheduled to enter clinical trials soon. SAN-HQ has established itself within the viral vector-based biopharmaceutical segment, where viruses are used to deliver genetic material into cells to treat or prevent disease. Due to safety concerns, regulators require manufacturers to minimize and control the amount of exogenous nucleic acids impurities (DNA or RNA not encapsulated by the vector) in the final dosage. Therefore, one or more nuclease treatments are often implemented in the downstream processing of the virus, in which the nuclease digests exogenous DNA. Exogenous DNA can also cause the viral particles to aggregate, which reduces both yield and potency of the vector. One of the key strategies to reduce aggregation involves keeping the virus at elevated salt concentrations. Unlike other commercially available nucleases, SAN-HQ digests nucleic acids with high efficiency at high salt concentrations. Furthermore SAN-HQ is utilized at much lower quantities which means less enzyme needs to be removed from the virus following its use which is another key advantage. To put it into context, the manufacturing process of viral vaccines is a complicated and lengthy multi-stage process with many steps. SAN-HQ is utilised for one part of this process and does not end up as part of the final therapeutic vaccine. Hence, the supply deal relates to the provision of this essential component to streamline part of the process. ReiThera, together with Leukocare AG (Germany) and Univercells S.A. (Belgium), has formed a pan-European consortium to fast-track the development of its vaccine against the novel coronavirus SARS-CoV-2, which causes COVID-19. ArcticZymes AS, CEO, Jethro Holter said: “We are delighted to expand our relationship in supporting ReiThera and its consortium partners with fast tracking its activities to develop a vaccine against the novel coronavirus SARS-CoV-2. ReiThera is a leading European company in genetic vaccine development focused on bringing innovative therapeutics to market via leveraging the best technologies such as ArcticZymes’ SAN-HQ. We look forward to supporting ReiThera in the development and future commercialisation of their vaccine.” “This agreement seamlessly fits with our efforts to scale up SAN-HQ which is supported by the Innovation Norway funding recently granted to ArcticZymes in May 2020. The timely scaling of SAN-HQ production will satisfy future commercial demand from our partners such as ReiThera.” ReiThera’s Project Manager, Marco Soriani, said: “ReiThera’s effort to develop a vaccine against the coronavirus that causes COVID-19 relies on its solid partnerships with key pharmaceutical stakeholders, such as ArcticZymes, which provide crucial technologies to ensure a consistently high-quality product. We look forward to working with ArcticZymes on this important product development program, which aims to tackle the global COVID-19 pandemic.” -ENDS- About ReiThera Srl ReiThera Srl is a biotech company dedicated to the technology development, GMP manufacturing and clinical translation of genetic vaccines and medicinal products for advanced therapies. The company’s management and scientific teams have developed a highly innovative technological platform based on simian adeno-vectored vaccines against several infectious diseases, such as RSV and Ebola. ReiThera is led by an experienced management team that has worked together for many years in previous successful enterprises, including Okairos (acquired by GSK), and has a long-standing expertise in scalable processes for viral vector manufacturing, supported by a cGMP facility inclusive of filling suite and quality control laboratories. ReiThera is also part of a pan-European consortium focused on the development and large-scale manufacture of an adeno-viral vector vaccine against COVID-19. ReiThera has its headquarters, R&D laboratories and GMP facilities in Rome, Italy.
OSL:AZTLong
by savepiginvest